ABIO Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 mai 2024 @ 22:00):

ARCA biopharma, Inc., a clinical-stage biopharmaceutical company, develops and commercializes genetically targeted therapies for cardiovascular diseases...

Stats
Dagens volum	16 801.00
Gjennomsnittsvolum	1.45M
Markedsverdi	47.29M
EPS	$0 ( 2024-04-24 )
Neste inntjeningsdato	( $0 ) 2024-07-19
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-7.76
ATR14	$0.0180 (0.55%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-30	Ma-weaver Jacob	Buy	6 000	Stock option (right to buy)
2024-01-30	Hove Anders D	Buy	6 000	Stock Option (right to buy)
2024-01-30	Mitchell Daniel J	Buy	6 000	Stock Option (right to buy)
2024-01-30	Flynn James P	Buy	6 000	Stock Option (right to buy)
2024-01-30	Conway Robert E	Buy	6 000	Stock Option (right to buy)

INSIDER POWER
98.24
Last 95 transactions
Buy: 2 938 848 \| Sell: 17 694 644

Volum Korrelasjon

Lang: 0.11 (neutral)

Kort: 0.05 (neutral)

Signal:(42.227) Neutral

ARCA Biopharma Inc Korrelasjon

10 Mest positive korrelasjoner
SCTL	0.977
LABP	0.957
MESO	0.952
MOTNU	0.943
NN	0.94
RMRM	0.933
VFF	0.932
STOK	0.928
AMRB	0.928
SMTC	0.927

10 Mest negative korrelasjoner
ATHN	-0.937
ARIZ	-0.926
AMD	-0.923
OSIS	-0.918
QQQM	-0.918
QQQ	-0.918
LULU	-0.916
CIFR	-0.916
CYN	-0.915
EZGO	-0.912

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

ARCA Biopharma Inc Korrelasjon - Valuta/Råvare

-0.03
( neutral )

0.27
( neutral )

0.00
( neutral )

-0.11
( neutral )

-0.45
( neutral )

-0.27
( neutral )

ARCA Biopharma Inc Økonomi

Annual	2023
Omsetning:	$0
Bruttogevinst:	$-111 000 (0.00 %)
EPS:	$-0.370

FY	2023
Omsetning:	$0
Bruttogevinst:	$-111 000 (0.00 %)
EPS:	$-0.370

FY	2022
Omsetning:	$0
Bruttogevinst:	$-114 000 (0.00 %)
EPS:	$-0.640

FY	2021
Omsetning:	$0.00
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-1.390

Financial Reports:

No articles found.

ARCA Biopharma Inc

ARCA biopharma, Inc., a clinical-stage biopharmaceutical company, develops and commercializes genetically targeted therapies for cardiovascular diseases. Its lead product candidates are Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), which is in Phase IIb clinical trial for the treatment for COVID-19; and Gencaro (bucindolol hydrochloride), a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with chronic heart failure. ARCA biopharma, Inc. has a collaboration agreement with LabCorp to develop genetic test for GENETIC-AF clinical trial; and research collaboration with Colorado Prevention Center, the University of Colorado's Academic Research Organization to develop and commercialize Gencaro. The company was incorporated in 2004 and is headquartered in Westminster, Colorado.